treatment with PLA,. At this stage it is impossible to say whether the presence of such large amounts of lysophospholipids has a role in isoenzyme inactivation. Nevertheless it can be hypothesized that each P450 isoenzyme responds differently to changes in membrane NEFA content and composition. This situation might facilitate the selective modulation of P450 isoenzyme activity depending on the overall requirements of the cell, tissue or body. For example, in the present study, the presence of NEFAs in the environment of the 3A family of isoenzymes seems to have a suppressing effect on the 6/%hydroxylation of testosterone. Consequently, the clearance of NEFAs from the membrane (perhaps in response to hormonal signals), would lead to enhanced testosterone hydroxylation, whereas the sequestration of excess dietary NEFAs in the membrane could lead to a further suppression of isoenzyme activity. Dirnerisation Interface pression of the bm3R1-C Y P l O2Al operon [lo] . Pretreatment of cultures with a non-metabolizable inducer of CYP102Al leads to a marked resistance to toxic fatty acids; a mutant strain that expresses a non-DNA binding form of Bm3Rl contains a high constitutive CYP102Al activity and a corresponding resistance to toxic fatty acids [6]. This system is conserved in Bacillus subtilis, which has allowed us to perform similar experiments and use the versatility of this species to dissect the genetics of the fatty acid hydroxylase system. T h e genetic context of the B. subtilis C YPlO2A3 gene closely resembles that of C YP102A1 in B . megaterium, with the P450 gene preceded by a gene (yrhl) encoding a transcriptional repressor that is similar to Bm3R1 ( Figure 1A ). Upstream of yrhl is an 18 bp inverted repeat that is almost identical to the operator of Bm3R1 in B. megaterium ( Figure   1B ). Both Bm3Rl and YrhI are very similar in their helix-turn-helix DNA binding domains and we have shown that both repressor proteins will bind to the operators from either Bacillus species (Figure 1 C) . T h e repressors are also highly similar in the two ligand-binding modules (LBMl and LBM2) that have been defined for the TetR repressor. This supports the notion that these repressors respond to similar fatty acid signals. Indeed, the expression of the yrhl-C YP102A3 operon can be induced with linoleic acid as assayed by P-galactosidase activity with a B . subtilis strain that harbours a transcriptional yrhT-lac2 fusion integrated in one copy in the non-essential amyE locus. YrhI has been shown to bind the 18 bp perfect inverted repeat in electrophoretic mobility-shift assays and has been shown to autoregulate the operon negatively in vivo. T h e /3-galactosidase production is higher in AyrhI (80 bp out-of-frame deletion) yrhT-lacZ and in Ayrhl-cypl02A3 yrhl'-lac2 strains compared with the strain harbouring the yrhT-lac2 fusion in a wild-type genetic background. Strains carrying transcriptional lac2 fusions with the yrhl promoter region, lacking respectively half of and the whole 18 bp inverted repeat, show higher pgalactosidase production compared with the strain with the promoter region encompassing the inverted repeat fused to l a d . When comparing the p-galactosidase production of strains carrying the yrhl'-lac2 fusion in wild-type, AC YP103A3 and Ayrhl-C YP102A3 genetic backgrounds, we found that the strain with C YP1 O2A3 deleted was intermediate. This indicates that the concentration of an inducer is higher in the absence of CYPl02A3. It remains to be seen whether the inducer is synthesized endogenously or is supplied in the growth medium used. The AC Y P l 0 2 A 3 strain was compared with the wildtype strain for its ability to grow on plates containing linoleic acid. We found that the P450-deleted strain has a greatly increased sensitivity to polyunsaturated fatty acids. This is the first genetic evidence that a CYP is required for an adaptive response to toxic fatty acids.
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It is clear, however, that the regulation of this operon is also under the control of multiple physiological signals. The transcription of the yrhI-C YP1 O2A3 operon is induced when grown in the presence of glucose. On 1 yo (w/v) glucose plates no difference can be seen in /?-galactosidase production between the yrhT-lacZ fusion-carrying strains with wild-type, AyrhI and AyrhI-C YP102A3 genetic backgrounds. The wild-type yrhI'-lac2 fusion strain shows a low level of /?-galactosidase production in NSMP (nutrient sporulation medium phosphate) liquid culture. In NSMP/1 yo (w/v) glucose liquid culture the production is higher and shows a cell-densitydependent pattern. /?-Galactosidase production increases during the exponential growth phase with the density of the culture and reaches a peak in the transition phase.
/?-Galactosidase production in a yrhI'-lac2 fusion strain with the spoOA gene deleted is almost abolished. SpoOA is the last component of the phospho-relay that integrates signals deciding whether or not the cell will initiate the developmental process of sporulation [l 11. The commitment to sporulation is dependent on the buildup of a threshold level of phosphorylated SpoOA in the cells; however, SpoOA is also a regulator of a wide range of stationary-phase phenomena and the deletion of spoOA has pleiotropic effects. Some of the phenotypes of a spoOA mutation can be reverted by a second mutation in the transition state regulator gene abrB. Phosphorylated SpoOA functions as a transcriptional activator of the early sporulation genes as well as a repressor of abrB. The deletion of abrB restores the expression of the yrhI'-lac2 fusion in a AspoOA background. The expression deficiency of the yrhI'-lacZ AspoOA strain can be complemented by growing close to wild-type B . subtilis, as well as to a AspoOA AabrB strain, indicating that AbrB negatively regulates the expression of a pheromone that is necessary for the full expression of the yrhI-C YP102A3 oper- The mammalian fatty acid hydroxylases encoded by the CYP4A genes are also regulated by a fatty acid-binding transcription factor. This fatty acid sensor is known as PPARo: (peroxisomeproliferator-activated receptor a). PPARo: is a member of the steroid hormone/nuclear receptor superfamily that acts as a fatty acid-activated transcription factor in the regulation of many genes that are required for lipid metabolism. Therefore this is the opposite regulatory mechanism to that seen in Bacillus species, where derepression is the mechanism. PPARa is expressed at high levels in the rodent liver and is activated by a wide range of compounds known as peroxisome proliferators that are known to cause alterations in lipid metabolism in hepatocytes. Peroxisome proliferators include the lipid-lowering fibrate drugs (Figure 1) ; the genetic ablation of PPARa in mice prevents the induction of the CYP4A genes and leads to increased hepatic lipid disposition in aging and on feeding with a high-fat diet [14] . This group of compounds is also known to cause liver cancer in rodents, although they are known not to be direct chemical mutagens. Peroxisome proliferators seem to modulate both the cell cycle and apoptosis processes in hepatocytes, which leads to hepatic hyperplasia and eventually tumorigenesis. These properties have led to the designation of peroxisome proliferators as nongenotoxic carcinogens. A key observation in the mechanism of action of peroxisome proliferators was the finding that the genetic ablation of PPARa in mouse abolishes both the changes in lipid metabolism and the formation of liver tumours in response to these chemicals [14] . However, the link (if any) is unclear between the regulation of the fatty acid hydroxylases and the carcinogenesis process.
Other PPARs, namely PPARG and PPARy, are expressed in tissues other than liver. A physiological role for PPARG has not been defined; however, PPARy has been described as being involved in a wide range of cellular processes. Initially, PPARy was described as a major regulator of adipogenesis, with the adipocyte-specific genes being transcriptionally controlled by PPARy [15, 16] . It has also been shown that the thiazolidenedione class of insulin-sensitizing drugs seem to work through the action of PPARy (Figure 2) [ 171. PPARy has now been found to be expressed and functional in the differentiation of many different cell types, including breast, colonic and prostate epithelium [18-211. PPARy has also been shown to be expressed in activated cells of the haemopoietic system such as macrophages and seems to antagonize the activated phenotype [22] . T h e expression in activated macrophages has led several investigators to speculate on the role of PPARy in the production of the atheroscleroticmacrophage-derived foam cell. Recent publications have suggested that PPARy might mediate the uptake and retention of lipid in macrophages, thus providing a pathological feedforward mechanism in atherogenesis [23, 24] . This is a tempting hypothesis owing to its known role in lipid accumulation in adipocytes. T o test this hypothesis we have developed an in vitro model of macro- We have shown that we can manipulate the lipid growth conditions of such cells so that they either differentiate into lipid-free macrophages or grossly lipid-loaded foam cells. Inclusion of PPARy activators such as rosiglitazone (BRL49653) into the culture medium results in no increases in lipid accumulation in the macrophage cultures and drastically depletes the intracellular lipid in the foam-cell cultures. T h e treatment of such cultures with rosiglitazone results in marked changes in gene expression, both increases in gene expression, such as that of the CD36 class B scavenger receptor, or in the repression of inflammatory cytokine expression. It is interesting to note that the classical scavenger receptor associated with atherosclerotic foam cells, SR-A, is markedly down-regulated by such treatment [22] . T h e induction mechanism of CD36 seems to be mediated by the binding of PPARy to an enhancer element in the CD36 regulatory sequences [23, 24] . T h e mechanism by which PPARy represses gene transcription has been shown to be the result of the inhibition of several signal-transduction processes. T h e direct molecular targets for PPARy in such a process have yet to be determined. Therefore it seems that PPARy might oppose many of the classical features of the atherogenic phenotype, while up-regulating certain pathways of lipid transport such as the CD36 pathway. This observation has important implications for the use of thiazolidenediones in the treatment of diabetes and atherosclerosis.
Another foam-cell model with similar pharmacology can be seen in glial cells. Glial cells are of central importance in the pathology of senile dementia, and are known to maintain or destroy neural integrity during aging. T h e expression of PPARy is highly inducible in these cells by inflammatory stimuli such as PMA and by treatment with rosiglitazone. We have found that human glial-derived cell lines accumulate lipid after treatment with polyunsaturated fatty acids and ligands for the retinoid X receptor. This lipid accumulation in such cell lines is again antagonized by rosiglitazone, again suggesting that, in certain cells associated with atherogenesis, PPARy mediates lipid clearance and that PPARy provides a powerful feedback response to lipid over!oad. This is in direct contrast with its function in adipocytes (Figure 2) . So far the only fatty acid hydroxylase that we have been able to detect in either cell system is CYPSA, thromboxane synth-ase. The expression of this enzyme is not increased by treatment with rosiglitazone. Our present challenge is to determine the downstream effectors of PPARy in the clearance of lipid in these cells and to determine the presence of fatty acid hydroxylases that might participate in these responses. 
Introduction
Fatty acids entering cells are rapidly esterified to the corresponding acyl-CoA esters, which have important roles in the degradation and synthesis of fatty acids and in their incorporation into complex lipids. The acyl-CoA esters are oxidized in mitochondria or peroxisomes, elongated and desaturated or esterified into complex lipids or posttranslationally to proteins. In addition, acyl-CoAs also act as potent feedback or competitive inhibitors and have important roles in intracellular Abbreviations used: CTE, cytosolic thioesteme; CYP, cytochrome P450; MTE, mitochondria1 thioesteme; PPAR. peroxisome-prolifetator-activated receptor; PTE, peroxisomal thioesterase. 'To whom correspondence should be addressed.
signalling. Recently acyl-CoAs were shown to act as ligands for hepatic nuclear factor 4a [l]. /?-Oxidation of fatty acids occurs in both mitochondria and peroxisomes ; both systems are highly regulated at the gene transcription level. The regulation of enzymes involved in the degradation and synthesis of lipids has been studied for a long time but it was only recently that more detailed information about molecular mechanisms of regulation has been revealed. More than 30 years ago, the fibrates were generated and found to be extremely efficient in lowering plasma triacylglycerol and cholesterol levels. These effects are attributed to an increased uptake of fatty acids from the circulation, increased oxidation in peroxisomes and mitochondria, decreased synthesis of fatty acids and triacylglycerols and decreased
